

Special Issue

Cardiomyopathies From Molecular Basis to Therapy

Message from the Guest Editor

In recent years, the AHA have defined cardiomyopathies as “a group of heterogeneous disorders of the myocardium due to a variety of causes that frequently are of genetic origin”. The diagnosis of cardiomyopathies has long been based on the morphology and function of the heart. The role of imaging in the early phenotyping of cardiac disease, risk assessment, and management guidance is expanding rapidly in ways previously thought not possible or realistic. Together with advances in cardiac imaging, advances in proteomics, metabolomics, microbiomics, and most of all in genetics, have broadened our understanding of the molecular and cellular deep mechanisms involved in the onset and progression of cardiomyopathies, which could potentially lead to the optimal treatment strategies for each patient. The purpose of this Special Issue is to review the scientific bases of non-ischemic cardiomyopathies. We will focus on progress in the current understanding of the onset and natural history of these conditions. Furthermore, we will discuss advancements in genetics and genomics, and the most recent discoveries on biomarkers and novel therapeutic targets.

Guest Editor

Dr. Giorgia Beffagna

Department of Cardiac, Thoracic, Vascular Sciences and Public Health,
University of Padova, 35131 Padova, Italy

Deadline for manuscript submissions

closed (15 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/91515

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).